Literature DB >> 29146271

Factors affecting the under-diagnosis of atypical ductal hyperplasia diagnosed by core needle biopsies - A 10-year retrospective study and review of the literature.

Michael Co1, Ava Kwong2, Tony Shek3.   

Abstract

INTRODUCTION: Due to the possibility of underestimation, surgical excision is usually offered to patients with atypical ductal hyperplasia (ADH) diagnosed with core needle biopsy (CNB). Here we review the 10-year data of patients with ADH diagnosed by CNB, aiming to identify the factors associated with under-diagnosis.
METHODS: Retrospective review of database from 1st Jan 2005 to 31st Dec 2014 was performed; patients with ADH diagnosed by CNB were identified. Diagnosis upgrade rate and its risk factors were evaluated.
RESULTS: 104 patients were found to have ADH on CNB, 101 patients received excisional biopsy while 3 patients refused operation. 34 patients had ductal carcinoma in situ (DCIS) after excision, 6 had invasive ductal carcinoma, 1 had lobular carcinoma in situ and 1 had angiosarcoma. CNB under-diagnosed up to 41.6% of malignant lesions. Breast mass on presentation and suspicious mammograms (BIRADS ≥ 4) are associated with diagnosis upgrade (P = 0.0005, 0.0001). Literature review of 39 studies between 1997 and 2017 revealed 3125 excision procedures performed for ADH diagnosed by CNB, the pooled median diagnosis upgrade rate was 25% (Range 4-54%).
CONCLUSION: We recommend excision in all patients with ADH diagnosed by CNB, especially in patients with suspicious mammographic features.
Copyright © 2017 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atypical ductal hyperplasia; Breast neoplasms; Core needle biopsy

Mesh:

Year:  2017        PMID: 29146271     DOI: 10.1016/j.ijsu.2017.11.005

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  6 in total

1.  Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia.

Authors:  Kate R Pawloski; Nicole Christian; Andrea Knezevic; Hannah Y Wen; Kimberly J Van Zee; Monica Morrow; Audree B Tadros
Journal:  Breast Cancer Res Treat       Date:  2020-08-28       Impact factor: 4.872

2.  Atypical Lesions of the Breast and Lobular Carcinoma in Situ in Pregnancy - Surgeons' Practice.

Authors:  Sadaf Alipour; Ramesh Omranipour; Frederic Amant; Bita Eslami
Journal:  Eur J Breast Health       Date:  2020-01-01

Review 3.  Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Authors:  Christoph J Rageth; Elizabeth A M O'Flynn; Katja Pinker; Rahel A Kubik-Huch; Alexander Mundinger; Thomas Decker; Christoph Tausch; Florian Dammann; Pascal A Baltzer; Eva Maria Fallenberg; Maria P Foschini; Sophie Dellas; Michael Knauer; Caroline Malhaire; Martin Sonnenschein; Andreas Boos; Elisabeth Morris; Zsuzsanna Varga
Journal:  Breast Cancer Res Treat       Date:  2018-11-30       Impact factor: 4.872

4.  Development and Validation of a Simple-to-Use Nomogram for Predicting the Upgrade of Atypical Ductal Hyperplasia on Core Needle Biopsy in Ultrasound-Detected Breast Lesions.

Authors:  Yun-Xia Huang; Ya-Ling Chen; Shi-Ping Li; Ju-Ping Shen; Ke Zuo; Shi-Chong Zhou; Cai Chang
Journal:  Front Oncol       Date:  2021-03-31       Impact factor: 6.244

5.  Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens.

Authors:  Christoph J Rageth; Ravit Rubenov; Cristian Bronz; Daniel Dietrich; Christoph Tausch; Ann-Katrin Rodewald; Zsuzsanna Varga
Journal:  Breast Cancer       Date:  2018-12-27       Impact factor: 4.239

6.  Effect of Chinese herbal medicine compound on breast hyperplasia: A protocol of systematic review.

Authors:  Hui-Lin Guan; Yu Wang; Yi-Fang Gui; Chun-Lei Zhang
Journal:  Medicine (Baltimore)       Date:  2020-12-04       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.